Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score < 1, 1-19, and >= 20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Burtness, B; Rischin, D; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BG; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Ge, J; Swaby, R; Gumuscu, B; Harrington, K

View this publication in the PUBMED database